NEPH vs NVCR vs NKTR vs CNMD

For growth investors, Nephros, Inc.

(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). CONMED Corporation (CNMD) offers the better valuation at 24. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 24.

3x versus Nephros, Inc. at 32. 0x.

Over the past 5 years, Nephros, Inc.

(NEPH) delivered a total return of -54. 4%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +38. 5% versus NKTR's -59. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 58β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 272% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nephros, Inc.

(NEPH) is pulling ahead at 32. 7% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nephros, Inc.

(NEPH) is the more profitable company, earning 6. 4% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNMD leads at 10. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CNMD: 112.

2% to $78. 00.

In this comparison, CNMD (2.

2% yield) pays a dividend. NEPH, NVCR, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Nephros, Inc.

(NEPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 58)). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NEPH: +11. 7%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NEPH is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; CNMD is a small-cap quality compounder stock. CNMD pays a dividend while NEPH, NVCR, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.